Study #2021-1157
MARGetuximab Or Trastuzumab (MARGOT): A phase II study comparing neoadjuvantpaclitaxel/margetuximab/pertuzumab to paclitaxel/trastuzumab/pertuzumab in patients with Stage II-III HER2-positive breast cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab
Description
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
Study phase:
Phase II
Physician name:
Paula Pohlmann
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-855-697-6460
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.